Evelo Biosciences Balance Sheet Health
Financial Health criteria checks 0/6
Evelo Biosciences has a total shareholder equity of $-26.7M and total debt of $33.9M, which brings its debt-to-equity ratio to -127.1%. Its total assets and total liabilities are $20.6M and $47.3M respectively.
Key information
-127.1%
Debt to equity ratio
US$33.95m
Debt
| Interest coverage ratio | n/a |
| Cash | US$17.26m |
| Equity | -US$26.71m |
| Total liabilities | US$47.33m |
| Total assets | US$20.63m |
Recent financial health updates
Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?
Aug 18
Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?
Mar 21Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?
Sep 25Recent updates
Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?
Aug 18Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03
Aug 11Marella Thorell is the new finance chief of Evelo Biosciences
Jul 18Evelo Biosciences: Hope After Dilution?
Jun 06Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?
Mar 21Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?
Sep 25What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?
Mar 11Evelo Bio secures ~$67.5M capital raise
Jan 29Evelo Biosciences expands EDP1815 mid-stage trial to atopic dermatitis
Jan 07Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares
Dec 15
Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?
Dec 11Evelo Biosciences identifies new lead oncology candidate
Dec 09Evelo Bio's EDP1815 completes enrollment targeting interim data in mid-stage psoriasis study
Dec 03Evelo Biosciences EPS beats by $0.04
Oct 29Financial Position Analysis
Short Term Liabilities: EVLO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EVLO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EVLO has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: EVLO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVLO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: EVLO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.4% each year